5-Gene-Multiplex 1% AF cfDNA in Plasma
The 5-Gene-Multiplex 1% AF cfDNA in Plasma from SensID is an advanced tool used for liquid biopsy assays, focusing on five important genetic mutations: AKT1, BRAF, KRAS, PIK3CA, and ERBB2. These mutations are critical in cancers such as lung, breast, colorectal, and melanoma and are key for targeted therapy decisions. Containing a 1% allelic frequency (AF) of these mutations, this product is ideal for use in digital PCR and next-generation sequencing (NGS). It acts as a positive control standard, essential for validating and developing sequencing protocols and PCR methods, and determining the detection limits of different diagnostic techniques. The mutations covered include: AKT1 (p.E17K), BRAF (p.V600E), KRAS (multiple variants), PIK3CA (p.E545K, p.H1047R), ERBB2 (p.Y772_A775dup). These mutations are directly linked to specific treatments, such as vemurafenib for BRAF and cetuximab for KRASmutations. The 5-Gene-Multiplex 1% AF cfDNA in Plasma product plays a pivotal role in improving the accuracy and reliability of liquid biopsy testing, facilitating more personalized cancer treatments by ensuring precision in mutation detection.
Quote-based, no public pricing. Add to your quote and our specialists put together a proposal with the right documentation, typically within 24 hours.
This kit in detail
The 5-Gene-Multiplex 1% AF cfDNA in Plasma from SensID is an advanced tool used for liquid biopsy assays, focusing on five important genetic mutations: AKT1, BRAF, KRAS, PIK3CA, and ERBB2. These mutations are critical in cancers such as lung, breast, colorectal, and melanoma and are key for targeted therapy decisions.
Containing a 1% allelic frequency (AF) of these mutations, this product is ideal for use in digital PCR and next-generation sequencing (NGS). It acts as a positive control standard, essential for validating and developing sequencing protocols and PCR methods, and determining the detection limits of different diagnostic techniques.
The mutations covered include:
- AKT1 (p.E17K),
- BRAF (p.V600E),
- KRAS (multiple variants),
- PIK3CA (p.E545K, p.H1047R),
- ERBB2 (p.Y772_A775dup).
These mutations are directly linked to specific treatments, such as vemurafenib for BRAF and cetuximab for KRASmutations. The 5-Gene-Multiplex 1% AF cfDNA in Plasma product plays a pivotal role in improving the accuracy and reliability of liquid biopsy testing, facilitating more personalized cancer treatments by ensuring precision in mutation detection.
- Comprehensive Mutation Detection: Includes critical mutations in AKT1, BRAF, KRAS, PIK3CA, and ERBB2.
- Reliable Positive Control: Serves as a standard for digital PCR and NGS.
- Ideal for Diagnostic Assays: Perfect for determining the detection limits and developing.
- Supports Targeted Therapies: Directly linked to therapeutic strategies.
The 5-Gene-Multiplex 1% AF cfDNA in Plasma product from SensID is a highly specialized and critical tool for liquid biopsy assays, primarily used in diagnostic and research applications. This product is designed to target five key mutations across essential genes: AKT1, BRAF, KRAS, PIK3CA, and ERBB2, mutations that are commonly linked to a range of cancers including lung, breast, colorectal, and melanoma. These mutations play an important role in cancer progression and are crucial for making informed therapeutic decisions.
The 5-Gene-Multiplex 1% AF cfDNA in Plasma contains a 1% allelic frequency (AF) of the targeted mutations. It serves as a positive control standard for techniques like digital PCR and next-generation sequencing (NGS). This tool is especially useful in validating and developing sequencing protocols, PCR methods, and assessing detection limits, which are crucial for achieving accurate and reliable results.
The specific mutations included in this product are:
- AKT1 (p.E17K),
- BRAF (p.V600E),
- KRAS (multiple variants),
- PIK3CA (p.E545K, p.H1047R),
- ERBB2 (p.Y772_A775dup).
These mutations are essential for targeted therapies. For example, BRAF mutations like p.V600E are treated with drugs such as vemurafenib, while KRAS mutations are addressed with therapies like cetuximab. Similarly, mutations in PIK3CA and AKT1 direct personalized treatments.
The 5-Gene-Multiplex 1% AF cfDNA in Plasma product is indispensable for advancing cancer diagnostics, especially in the rapidly evolving field of liquid biopsy testing. By providing a reliable and accurate benchmark, it helps facilitate the development of more precise and personalized cancer treatments, ensuring that assays used for liquid biopsy can detect genetic mutations with confidence and clarity.
5-Gene-Multiplex 1% AF cfDNA in Plasma
Datasheets and regulatory documentation
Everything your quality team needs for evaluation and procurement.
Frequently paired with this kit
Other assays and instruments lab teams add alongside the 5-Gene-Multiplex 1% AF cfDNA in Plasma.
Plasma 1x (Human-Tech) DNA Free 1000 ml
Add this kit to your quote
Tell us the platforms and throughput you’re planning for and our specialists will put together a clear proposal with the right documentation, no public pricing, just a considered answer.
